Nonversion: AbbVie – Shire deal falls through but inversions will continue
The impact of a US Treasury Notice to reduce the benefits of tax inversion deals is taking effect. AbbVie has scrapped its proposed $54 billion takeover of Shire, and Salix and Cosmo have decided not to combine either.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: